Citigroup Lowers Merus (MRUS) Price Target to $16.00

Share on StockTwits

Merus (NASDAQ:MRUS) had its price objective decreased by equities researchers at Citigroup from $18.00 to $16.00 in a research report issued on Friday. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. Citigroup‘s price objective suggests a potential upside of 27.90% from the company’s previous close.

A number of other research analysts have also commented on the stock. Zacks Investment Research raised shares of Merus from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Friday. BidaskClub raised shares of Merus from a “sell” rating to a “hold” rating in a research report on Thursday, March 7th. Finally, ValuEngine raised shares of Merus from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $21.67.

Shares of MRUS traded down $0.62 during trading hours on Friday, reaching $12.51. 2,758 shares of the company traded hands, compared to its average volume of 25,588. The firm has a market capitalization of $303.29 million, a P/E ratio of -2.92 and a beta of -0.12. Merus has a 1-year low of $11.00 and a 1-year high of $26.74.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, December 27th. The biotechnology company reported ($0.55) EPS for the quarter. The company had revenue of $7.57 million for the quarter, compared to analyst estimates of $4.25 million. Merus had a negative net margin of 140.49% and a negative return on equity of 55.96%. Equities research analysts predict that Merus will post -2.18 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its stake in Merus by 18.8% in the fourth quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 2,373 shares during the period. Squarepoint Ops LLC increased its stake in Merus by 10.3% in the fourth quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 1,100 shares during the period. Artal Group S.A. bought a new stake in Merus in the fourth quarter valued at about $2,886,000. Morgan Stanley increased its stake in Merus by 74.3% in the third quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after acquiring an additional 30,538 shares during the period. Finally, Aquilo Capital Management LLC increased its stake in Merus by 3.6% in the third quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock valued at $25,577,000 after acquiring an additional 44,799 shares during the period. 58.76% of the stock is currently owned by institutional investors and hedge funds.

About Merus

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Recommended Story: What causes a recession?

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.